Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ928MR)

This product GTTS-WQ928MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ928MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10532MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ11469MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ14670MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ2586MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ1148MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ13820MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ15764MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ7936MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-3359609
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW